MP 101-Mediti Pharma

Drug Profile

MP 101-Mediti Pharma

Alternative Names: LY-2979165; MP-101-Mediti Pharma

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Mediti Pharma
  • Class Antipsychotics; Dicarboxylic acids; Small molecules; Triazoles
  • Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Bipolar disorders

Most Recent Events

  • 04 May 2017 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (PO)
  • 06 May 2016 Chemical structure information added
  • 27 Apr 2016 Discontinued - Phase-I for Bipolar disorders (In volunteers) in Singapore & United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top